HK1116087A1 - Ski 606 as src kinase inhibitor for treating osteolytic lesions src ski 606 - Google Patents

Ski 606 as src kinase inhibitor for treating osteolytic lesions src ski 606

Info

Publication number
HK1116087A1
HK1116087A1 HK08109456.0A HK08109456A HK1116087A1 HK 1116087 A1 HK1116087 A1 HK 1116087A1 HK 08109456 A HK08109456 A HK 08109456A HK 1116087 A1 HK1116087 A1 HK 1116087A1
Authority
HK
Hong Kong
Prior art keywords
ski
src
kinase inhibitor
osteolytic lesions
treating osteolytic
Prior art date
Application number
HK08109456.0A
Other languages
English (en)
Chinese (zh)
Inventor
Bryant G Darnay
Janet E Price
Ann Poblenz
Moshe Talpaz
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of HK1116087A1 publication Critical patent/HK1116087A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK08109456.0A 2005-06-17 2008-08-26 Ski 606 as src kinase inhibitor for treating osteolytic lesions src ski 606 HK1116087A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69193305P 2005-06-17 2005-06-17
PCT/US2006/023529 WO2006138590A1 (en) 2005-06-17 2006-06-16 Inhibition of osteolytic lesions by src kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1116087A1 true HK1116087A1 (en) 2008-12-19

Family

ID=37570781

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08109456.0A HK1116087A1 (en) 2005-06-17 2008-08-26 Ski 606 as src kinase inhibitor for treating osteolytic lesions src ski 606

Country Status (18)

Country Link
US (1) US7468379B2 (da)
EP (1) EP1896020B1 (da)
JP (1) JP5121706B2 (da)
KR (2) KR20140036336A (da)
CN (2) CN101242835A (da)
AU (1) AU2006259243B2 (da)
BR (1) BRPI0613146B8 (da)
CA (1) CA2612333C (da)
DK (1) DK1896020T3 (da)
ES (1) ES2509875T3 (da)
HK (1) HK1116087A1 (da)
IL (1) IL188146A (da)
MX (1) MX2007016230A (da)
NZ (1) NZ564507A (da)
PL (1) PL1896020T3 (da)
PT (1) PT1896020E (da)
SI (1) SI1896020T1 (da)
WO (1) WO2006138590A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109953986A (zh) * 2019-04-04 2019-07-02 泉州师范学院 一种小分子抑制剂azin53及其在制药中的应用
WO2021245677A1 (en) * 2020-06-05 2021-12-09 Digestix Bioscience Inc. Compositions and methods for treating dysplastic and early-stage neoplastic conditions
WO2024054793A1 (en) * 2022-09-09 2024-03-14 University Of Rochester Inhibition of efferocytosis as a treatment to prevent bone loss and increase bone density and strength

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
JPH10287679A (ja) * 1997-04-11 1998-10-27 Takeda Chem Ind Ltd Ｔａｎ−２４８３関連化合物、その製造法および用途
IL150061A0 (en) * 1999-12-17 2002-12-01 Ariad Pharma Inc Purine derivatives
IL150059A0 (en) * 1999-12-17 2002-12-01 Ariad Pharma Inc Novel heterocycles
US20030045480A1 (en) 2001-07-09 2003-03-06 Pavel Safar Method of treating hyperresorptive bone disorders
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
JP2005008581A (ja) * 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
JP2005089352A (ja) * 2003-09-16 2005-04-07 Kissei Pharmaceut Co Ltd 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途
RU2006113691A (ru) 2003-11-06 2007-12-20 Вайет (Us) Применение 4-анилин-3-хинолинкарбонитрилов для лечения хронической миелогенной лейкемии (cml)

Also Published As

Publication number Publication date
CN101242835A (zh) 2008-08-13
MX2007016230A (es) 2008-03-06
WO2006138590A1 (en) 2006-12-28
DK1896020T3 (da) 2014-10-27
IL188146A0 (en) 2008-06-05
BRPI0613146A2 (pt) 2010-12-21
PT1896020E (pt) 2014-10-28
NZ564507A (en) 2010-12-24
JP5121706B2 (ja) 2013-01-16
US20070004748A1 (en) 2007-01-04
CA2612333C (en) 2013-12-17
EP1896020A4 (en) 2010-11-24
AU2006259243B2 (en) 2011-04-21
SI1896020T1 (sl) 2014-11-28
PL1896020T3 (pl) 2015-02-27
CN103705517A (zh) 2014-04-09
BRPI0613146B8 (pt) 2021-05-25
BRPI0613146B1 (pt) 2020-08-11
ES2509875T3 (es) 2014-10-20
KR20080030025A (ko) 2008-04-03
JP2008543870A (ja) 2008-12-04
EP1896020A1 (en) 2008-03-12
CA2612333A1 (en) 2006-12-28
KR101385488B1 (ko) 2014-04-15
KR20140036336A (ko) 2014-03-25
EP1896020B1 (en) 2014-08-20
IL188146A (en) 2016-04-21
US7468379B2 (en) 2008-12-23
AU2006259243A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
HK1114380A1 (en) Pyrrolopyrazoles as kinase inhibitors
TWI370127B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
HK1133641A1 (zh) 激酶抑製劑化合物
HK1135391A1 (en) Triazole derivatives as kinase inhibitors
IL177278A0 (en) Pyrazolotriazines as kinase inhibitors
IL190078A0 (en) Kinase inhibitors
IL186845A0 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
PL1891066T3 (pl) Związki i kompozycje jako inhibitory kinazy białkowej
EP1841431A4 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
SI1910348T1 (sl) Spojine benzotiazola in azabenzotiazola, uporabne kot kinazni inhibitorji
IL192298A0 (en) Heterocyclic janus kinase 3 inhibitors
EP1778693A4 (en) AS KINASEINHIBITORS USEFUL COMPOUNDS OF TRICYCLIC HETEROARYL
IL197381A0 (en) Kinase inhibitor
SI1943243T1 (sl) Inhibotorji kinaz
ZA200803636B (en) Triazole compounds as lipoxygenase inhibitors
PL1896422T3 (pl) Inhibitory kinazy tyrozynowej
EP1951252A4 (en) INHIBITORS OF TYROSINE KINASES
HK1116087A1 (en) Ski 606 as src kinase inhibitor for treating osteolytic lesions src ski 606
ZA200709732B (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
EP1940411A4 (en) MACROHETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
ZA200706212B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
IL189985A0 (en) Kinase inhibitors
ZA200803287B (en) Kinase inhibitors